Zymeworks Inc.(ZYME)

$28.67—

Chart

Zymeworks Inc.(ZYME)

NASDAQ

$28.67—

Chart Studio

ZYME(ZYME)

ZYME

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$2.17

Nov 5, 2026

Revenue Estimate

$212M

FY2026E EPS$1.31

FY2027E EPS$1.01

Analyst Sentiment

Wall St. Consensus

Buy

21 analysts·High coverage

Score

19 Buy (90%)2 Hold (10%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1990%

Hold

210%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$32.00

+11.6%

Consensus

$46.00

+60.4%

Bull

$51.00

+77.9%

12-Month Target Range21 analysts

$32.00$46.00$51.00

Current $28.67Consensus

Current Price

$28.67

Upside to Consensus

$17.33

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-2.43%

EPS-22.59%

FY2028

Rev-18.74%

EPS-92.78%

FY2029

Rev+46.12%

EPS+1208.60%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$302M	$295M	$239M	$350M	$442M
Low	$265M	$112M	$163M	$251M	$317M
High	$392M	$438M	$308M	$464M	$587M
EBITDA Avg	$-199M	$-195M	$-158M	$-231M	$-292M
Low	$-259M	$-289M	$-204M	$-307M	$-387M
High	$-175M	$-74M	$-107M	$-166M	$-209M
EBIT Avg	$-208M	$-203M	$-165M	$-240M	$-304M
Low	$-270M	$-301M	$-212M	$-319M	$-403M
High	$-182M	$-77M	$-112M	$-172M	$-218M
Net Income Avg	$87M	$123M	$12M	$72M	$117M
Low	$24M	$-3.27B	$-36M	$45M	$74M
High	$194M	$3.50B	$59M	$103M	$167M
EPS Avg	$1.31	$1.01	$0.07	$0.95	$1.55
Low	$0.32	$-43.45	$-0.48	$0.60	$0.98
High	$2.58	$46.49	$0.78	$1.36	$2.21
Analysts (Rev / EPS)	6 / 5	6 / 6	6 / 5	4 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$212M	$86M	$59M	$60M	$76M	$34M
Low	$203M	$15M	$26M	$27M	$34M	$15M
High	$217M	$203M	$95M	$97M	$122M	$54M
EBITDA Avg	$-140M	$-57M	$-39M	$-40M	$-50M	$-22M
Low	$-143M	$-134M	$-63M	$-64M	$-81M	$-36M
High	$-134M	$-10M	$-17M	$-18M	$-22M	$-10M
EBIT Avg	$-146M	$-59M	$-41M	$-42M	$-52M	$-23M
Low	$-149M	$-139M	$-65M	$-67M	$-84M	$-37M
High	$-140M	$-10M	$-18M	$-18M	$-23M	$-10M
Net Income Avg	$158M	$23M	$-6M	$-9M	$-364,966	$-3M
Low	$133M	$-160M	$-11M	$-16M	$-652,793	$-5M
High	$168M	$92M	$-2M	$-2M	$-99,951	$-799,615
EPS Avg	$2.17	$0.31	$-0.09	$-0.12	$-0.01	$-0.04
Low	$1.83	$-2.20	$-0.16	$-0.21	$-0.01	$-0.07
High	$2.31	$1.25	$-0.02	$-0.03	$-0.00	$-0.01
Analysts (Rev / EPS)	4 / 5	5 / 5	4 / 3	4 / 3	4 / 3	4 / 3

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Truist Financial

Zymeworks price target raised to $32 from $31 at Truist

Target:$32.00

+34.6%from $23.77

Aug 7, 2026Stifel Nicolaus

Zymeworks price target lowered to $46 from $47 at Stifel

Target:$46.00

+90.8%from $24.11

Aug 7, 2026Wells Fargo

Zymeworks price target raised to $40 from $37 at Wells Fargo

Target:$40.00

+72.9%from $23.13

Aug 5, 2026H.C. Wainwright

Zymeworks price target raised to $51 from $46 at H.C. Wainwright

Target:$51.00

+116.4%from $23.57

Jul 7, 2026Truist Financial

Zymeworks price target raised to $31 from $28 at Truist

Target:$31.00

+17.2%from $26.45

Jun 30, 2026Wells Fargo

Zymeworks price target raised to $37 from $34 at Wells Fargo

Target:$37.00

+53.5%from $24.10

Jun 9, 2026Truist Financial

Truist Securities Assumes Zymeworks (ZYME) at Buy

Target:$28.00

+17.0%from $23.93

Jun 3, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)

Target:$46.00

+90.8%from $24.11

Mar 9, 2026Evercore ISI

Zymeworks price target raised to $48 from $33 at Evercore ISI

Target:$48.00

+97.9%from $24.25

Dec 17, 2025Truist Financial

Zymeworks initiated with a Buy at Truist

Target:$40.00

+54.7%from $25.85

Dec 12, 2025Wells Fargo

Zymeworks upgraded to Overweight from Equal Weight at Wells Fargo

Target:$33.00

+32.4%from $24.93

Dec 3, 2025JMP Securities

Zymeworks initiated with an Outperform at Citizens JMP

Target:$32.00

+27.5%from $25.10

Nov 19, 2025Wells Fargo

Zymeworks (ZYME) PT Raised to $25 at Wells Fargo

Target:$25.00

+8.7%from $22.99

Nov 19, 2025Stifel Nicolaus

Zymeworks (ZYME) PT Raised to $40 at Stifel

Target:$40.00

+74.0%from $22.99

Nov 17, 2025Leerink Partners

Zymeworks price target raised to $37 from $24 at Leerink

Target:$37.00

+54.8%from $23.90

Oct 14, 2025H.C. Wainwright

Zymeworks upgraded to Buy from Neutral at H.C. Wainwright

Target:$26.00

+43.6%from $18.11

Nov 21, 2024Leerink Partners

Zymeworks (ZYME) PT Raised to $26 at Leerink Partners

Target:$26.00

+90.1%from $13.68

Nov 1, 2024Wells Fargo

Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight

Target:$12.00

-9.6%from $13.28

Oct 28, 2024Stifel Nicolaus

Zymeworks (ZYME) PT Raised to $28 at Stifel

Target:$28.00

+113.6%from $13.11

Sep 25, 2024H.C. Wainwright

Zymeworks price target raised to $12 from $10 at H.C. Wainwright

Target:$12.00

-4.0%from $12.50

Sep 18, 2024H.C. Wainwright

H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)

Target:$10.00

-18.7%from $12.30

Sep 10, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Zymeworks (ZYME)

Target:$21.00

+78.7%from $11.75

Dec 19, 2022Jefferies

Zymeworks upgraded to Buy from Hold at Jefferies

Target:$11.00

+62.0%from $6.79

Nov 1, 2022H.C. Wainwright

H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility

Target:$8.00

+9.7%from $7.29

Sep 20, 2021H.C. Wainwright

Analysts Offer Insights on Healthcare Companies: Seagen (NASDAQ: SGEN), Genmab (NASDAQ: GMAB) and Zymeworks (NYSE: ZYME)

Target:$44.00

+33.1%from $33.07

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance